In a major cross-border pharmaceutical crackdown, federal prosecutors in the United States have indicted two Indian nationals for orchestrating an international smuggling network that imported counterfeit versions of the blockbuster diabetes and weight loss drug Ozempic from unauthorized manufacturers in China. The indictment, returned by a federal grand jury in the Middle District of Florida, charges Swapandeep Roy and Vicky Ramancha along with several unnamed co-conspirators. The defendants are accused of sourcing illicit consignments of the injectable semaglutide imitation and offloading them to wholesale pharmaceutical distributors across the United States at discounted wholesale rates, exploiting soaring domestic consumer demand and widespread clinical supply shortages.

Extradition From Italy, Absconding Partner, and Potential 71-Year Federal Sentence

According to an official release by the US Department of Justice (DOJ), the legal dragnet tightened following an international operation that saw Swapandeep Roy apprehended in Italy and extradited to the United States. Roy entered a plea of not guilty during his initial arraignment before a federal magistrate in Tampa, Florida, while co-conspirator Vicky Ramancha continues to evade authorities and remains an active fugitive. Court filings reveal that if convicted on all counts—including conspiracy to defraud the United States, smuggling counterfeit goods, and trafficking misbranded prescription pharmaceuticals—the defendants face a cumulative statutory maximum sentence of up to 71 years in federal prison.

Sophisticated Knockoffs Evaded FDA Warnings and Targeted Vulnerable Patients

Investigators detailed that between July 2023 and April 2024, the syndicate procured large volumes of fake Ozempic engineered with deceptively precise packaging, counterfeit informational leaflets, forged batch labels, and unverified pre-filled injection needles designed specifically to deceive retail distributors, pharmacists, and end consumers. Authentic Ozempic, a semaglutide injectable, routinely costs uninsured American patients hundreds of dollars per monthly course. Federal prosecutors underscored that the defendants brazenly continued their illicit distribution operation even after the US Food and Drug Administration (FDA) intercepted suspicious shipments in December 2023 and broadcast public safety warnings. Assistant Attorney General A. Tyson Duva of the Justice Department's Criminal Division warned that black-market prescription counterfeits pose catastrophic risks to public health and undermine the structural integrity of the national healthcare supply chain.